In vitro susceptibilities of Rickettsia and Bartonella spp. to 14-hydroxy-clarithromycin as determined by immunofluorescent antibody analysis of infected Vero cell monolayers

被引:18
作者
Ives, TJ
Marston, EL
Regnery, RL
Butts, JD
Majerus, TC
机构
[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Sch Med, Dept Family Med, Chapel Hill, NC 27599 USA
[3] Ctr Dis Control & Prevent, Viral & Rickettsial Branch, Atlanta, GA USA
[4] Univ N Carolina Hosp, Dept Pharm, Chapel Hill, NC USA
[5] Abbott Labs, Abbott Pk, IL 60064 USA
关键词
D O I
10.1093/jac/45.3.305
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in vitro susceptibilities of Rickettsia akari, Rickettsia conorii, Rickettsia prowazekii, Rickettsia rickettsii, Bartonella elizabethae, Bartonella henselae and Bartonella quintana to different concentrations of clarithromycin, 14-hydroxy-clarithromycin (the primary metabolite of clarithromycin) and tetracycline in Vero cell cultures, were determined by enumeration of immunofluorescently-stained bacilli. The extent of antibiotic-induced inhibition of fool was recorded for each dilution of antibiotic and compared with an antibiotic-negative control. Based upon MIC data, clarithromycin alone is highly active against all three Bartonella spp., R. akari and R. prowazekii, while 14-hydroxy-clarithromycin is active against R, conorii, R. prowazekii and R. rickettsii. Further testing is warranted in animal models and human clinical trials, to examine the activity of both clarithromycin and its primary metabolite and to define further the role of clarithromycin in therapy, particularly of infections caused by obligate intracellular bacteria such as Rickettsia and Bartonella spp.
引用
收藏
页码:305 / 310
页数:6
相关论文
共 34 条
[21]   The in-vitro anti-rickettsial activity of macrolides [J].
Keysary, A ;
Itzhaki, A ;
Rubinstein, E ;
Oron, C ;
Keren, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 38 (04) :727-731
[22]   ISOLATION OF ROCHALIMAEA SPECIES FROM CUTANEOUS AND OSSEOUS LESIONS OF BACILLARY ANGIOMATOSIS [J].
KOEHLER, JE ;
QUINN, FD ;
BERGER, TG ;
LEBOIT, PE ;
TAPPERO, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (23) :1625-1631
[23]   UPTAKE, ACCUMULATION, AND EGRESS OF ERYTHROMYCIN BY TISSUE-CULTURE CELLS OF HUMAN-ORIGIN [J].
MARTIN, JR ;
JOHNSON, P ;
MILLER, MF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (03) :314-319
[24]   ANTIMICROBIAL SUSCEPTIBILITY OF ROCHALIMAEA-QUINTANA, ROCHALIMAEA-VINSONII, AND THE NEWLY RECOGNIZED ROCHALIMAEA-HENSELAE [J].
MAURIN, M ;
RAOULT, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 (04) :587-594
[25]   IN-VITRO SUSCEPTIBILITIES OF SPOTTED-FEVER GROUP RICKETTSIAE AND COXIELLA-BURNETII TO CLARITHROMYCIN [J].
MAURIN, M ;
RAOULT, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (12) :2633-2637
[26]   MICS OF 28 ANTIBIOTIC COMPOUNDS FOR 14 BARTONELLA (FORMERLY ROCHALIMAEA) ISOLATES [J].
MAURIN, M ;
GASQUET, S ;
DUCCO, C ;
RAOULT, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (11) :2387-2391
[27]   MICS AND MBCS OF CLARITHROMYCIN AGAINST MYCOBACTERIUM-AVIUM WITHIN HUMAN MACROPHAGES [J].
MOR, N ;
HEIFETS, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (01) :111-114
[28]   LACK OF BACTERICIDAL EFFECT OF ANTIBIOTICS EXCEPT AMINOGLYCOSIDES ON BARTONELLA (ROCHALIMAEA) HENSELAE [J].
MUSSO, D ;
DRANCOURT, M ;
RAOULT, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (01) :101-108
[29]   CHARACTERIZATION OF A NOVEL ROCHALIMAEA SPECIES, R-HENSELAE SP-NOV, ISOLATED FROM BLOOD OF A FEBRILE, HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE PATIENT [J].
REGNERY, RL ;
ANDERSON, BE ;
CLARRIDGE, JE ;
RODRIGUEZBARRADAS, MC ;
JONES, DC ;
CARR, JH .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (02) :265-274
[30]   In vitro susceptibilities of 27 rickettsiae to 13 antimicrobials [J].
Rolain, JM ;
Maurin, M ;
Vestris, G ;
Raoult, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (07) :1537-1541